FDA approves expanded indication for Merck’s KEYTRUDA in adult patients with relapsed or refractory cHL

This article was originally published here

The approval is based on results from the Phase 3 KEYNOTE-204 trial in which KEYTRUDA significantly reduced the risk of disease progression or death by 35% (HR=0.65 [95%

The post FDA approves expanded indication for Merck’s KEYTRUDA in adult patients with relapsed or refractory cHL appeared first on Pharmaceutical Business review.